{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Prep-San Ultra by Ecolab Inc.
(2015)
Source URL:
First approved in 2015
Source:
Prep-San Ultra by Ecolab Inc.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT02418130: Phase 4 Interventional Completed Fatigue
(2014)
Source URL:
First approved in 2015
Source:
V.S. Power / Vacsu Power (Dynamic and Powerful 99 year life) by Mercylignt
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 348
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NovaFerrum Multivitamin with Iron Pediatric Drops by Gensavis Pharmaceuticals, LLC
(2015)
Source URL:
First approved in 2015
Source:
NovaFerrum Multivitamin with Iron Pediatric Drops by Gensavis Pharmaceuticals, LLC
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2020)
Source URL:
First approved in 2015
Source:
21 CFR 347
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 333E
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M016
(2014)
Source URL:
First approved in 2014
Source:
M016
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT02569632: Phase 4 Interventional Completed Meningococcal Infections
(2015)
Source URL:
First approved in 2014
Source:
BLA125549
Source URL:
Class:
MIXTURE